Cord blood chimerism and relapse after haplo-cord transplantation

References

• Lindemans CA, van Besien K. Topping it up: methods to improve cord blood transplantation outcomes by increasing the number of CD34+ cells. Cytotherapy. 2015;17:723–729.
   PubMed Web of Science ®Google Scholar
• Liu H, van Besien K. Alternative donor transplantation–”mixing and matching”: the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors? Curr Hematol Malig Rep. 2015;10:1–7.
   PubMed Web of Science ®Google Scholar
• Kwon M, Bautista G, Balsalobre P, et al. Haplo-cord transplantation using CD34+ cells from a third-party donor to speed engraftment in high-risk patients with hematologic disorders. Biol Blood Marrow Transplant. 2014;20:2015–2022.
   PubMed Web of Science ®Google Scholar
• Liu H, Rich ES, Godley L, et al. Reduced-intensity conditioning with combined haploidentical and cord blood transplantation results in rapid engraftment, low GVHD, and durable remissions. Blood. 2011;118:6438–6445.
   PubMed Web of Science ®Google Scholar
• van Besien K, Hari P, Zhang MJ, et al. Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and survival free of progression and GVHD (GRFS). Haematol. 2016;101:634–643.
   PubMed Web of Science ®Google Scholar
• Tsai SB, Liu H, Shore T, et al. Frequency and risk factors associated with cord graft failure (cgf) after transplant with single unit umbilical cord cells supplemented by haploidentical cells (haplo-cord) with reduced-intensity conditioning. Biol Blood Marrow Transplant. 2016;22:1065–1072.
   PubMed Web of Science ®Google Scholar
• Barker JN, Byam C, Scaradavou A. How I treat: the selection and acquisition of unrelated cord blood grafts. Blood. 2011;117:2332–2339.
   PubMed Web of Science ®Google Scholar
• Eapen M, Klein JP, Ruggeri A, et al. Impact of allele-level HLA matching on outcomes after myeloablative single unit umbilical cord blood transplantation for hematologic malignancy. Blood. 2014;123:133–140.
   PubMed Web of Science ®Google Scholar
• Yoshihara S, Taniguchi K, Ogawa H, et al. The role of HLA antibodies in allogeneic SCT: is the 'type-and-screen' strategy necessary not only for blood type but also for HLA? Bone Marrow Transplant. 2012;47:1499–1506.
   PubMed Web of Science ®Google Scholar
• Gergis U, Mayer S, Gordon B, et al. A strategy to reduce donor-specific HLA Abs before allogeneic transplantation. Bone Marrow Transplant. 2014;49:722–724.
   PubMed Web of Science ®Google Scholar
• Van Besien KW, Demuynck H, LeMaistre CF, et al. High dose melphalan allows durable engraftment of allogeneic bone marrow. Bone Marrow Transplant. 1995;15:321–323.
   PubMed Web of Science ®Google Scholar
• Giralt S, Thall PF, Khouri I I, et al. Melphalan and purine analog-containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation. Blood. 2001;97:631–637.
   PubMed Web of Science ®Google Scholar
• Rennert H, Leonard DG, Cushing M, et al. Avoiding pitfalls in bone marrow engraftment analysis: a case study highlighting the weakness of using buccal cells for determining a patient's constitutional genotype after hematopoietic stem cell transplantation. Cytotherapy. 2013;15:391–395.
   PubMed Web of Science ®Google Scholar
• Klein JP, Rizzo JD, Zhang MJ, et al. Statistical methods for the analysis and presentation of the results of bone marrow transplants. Part 2: Regression modeling. Bone Marrow Transplant. 2001;28:1001–1011.
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123:3664–3671.
   PubMed Web of Science ®Google Scholar
• Armand P, Kim HT, Cutler CS, et al. Prognostic impact of elevated pretransplantation serum ferritin in patients undergoing myeloablative stem cell transplantation. Blood. 2007;109:4586–4588.
   PubMed Web of Science ®Google Scholar
• Sorror M, Storer B, Sandmaier BM, et al. Hematopoietic cell transplantation-comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. Cancer. 2008;112:1992–2001.
   PubMed Web of Science ®Google Scholar
• Artz AS, Wickrema A, Dinner S, et al. Pretreatment C-reactive protein is a predictor for outcomes after reduced-intensity allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2008;14:1209–1216.
   PubMed Web of Science ®Google Scholar
• Ponce DM, Hilden P, Devlin SM, et al. High disease-free survival with enhanced protection against relapse after double-unit cord blood transplantation when compared with t cell-depleted unrelated donor transplantation in patients with acute leukemia and chronic myelogenous leukemia. Biol Blood Marrow Transplant. 2015;21:1985–1993.
   PubMed Web of Science ®Google Scholar
• Verneris MR, Brunstein CG, Barker J, et al. Relapse risk after umbilical cord blood transplantation: enhanced graft-versus-leukemia effect in recipients of 2 units. Blood. 2009;114:4293–4299.
   PubMed Web of Science ®Google Scholar
• Hiwarkar P, Qasim W, Ricciardelli I, et al. Cord blood T cells mediate enhanced antitumor effects compared with adult peripheral blood T cells. Blood. 2015;126:2882–2891.
   PubMed Web of Science ®Google Scholar
• Mold JE, McCune JM. Immunological tolerance during fetal development. Adv Immunol. 2012:73–111.
   Google Scholar
• van Rood JJ, Scaradavou A, Stevens CE. Indirect evidence that maternal microchimerism in cord blood mediates a graft-versus-leukemia effect in cord blood transplantation. Proc Nat Acad Sci USA. 2012;109:2509–2514.
   PubMed Web of Science ®Google Scholar
• Ringden O, Labopin M, Ciceri F, et al. Is there a stronger graft-versus-leukemia effect using HLA-haploidentical donors compared with HLA-identical siblings? Leukemia. 2016;30:447–455.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood. 2011;118:282–288.
   PubMed Web of Science ®Google Scholar
• Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide versus matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126:1033–1040.
   PubMed Web of Science ®Google Scholar
• Kasamon YL, Bolanos-Meade J, Prince GT, et al. Outcomes of nonmyeloablative hla-haploidentical blood or marrow transplantation with high-dose post-transplantation cyclophosphamide in older adults. J Clin Oncol. 2015;33:3152–3161.
   PubMed Web of Science ®Google Scholar
• Crucitti L, Crocchiolo R, Toffalori C, et al. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation. Leukemia. 2015;29:1143–1152.
   PubMed Web of Science ®Google Scholar
• Vago L, Toffalori C, Ciceri F, et al. Genomic loss of mismatched human leukocyte antigen and leukemia immune escape from haploidentical graft-versus-leukemia. Semin Oncol. 2012;39:707–715.
   PubMed Web of Science ®Google Scholar
• Koreth J, Kim HT, Nikiforow S, et al. Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant. 2014;20:1516–1521.
   PubMed Web of Science ®Google Scholar
• Lee HC, Saliba RM, Rondon G, et al. Mixed T lymphocyte chimerism after allogeneic hematopoietic transplantation is predictive for relapse of acute myeloid leukemia and myelodysplastic syndromes. Biol Blood Marrow Transplant. 2015;21:1948–1954.
   PubMed Web of Science ®Google Scholar
• van Besien K, Dew A, Lin S, et al. Patterns and kinetics of T-cell chimerism after allo transplant with alemtuzumab-based conditioning: mixed chimerism protects from GVHD, but does not portend disease recurrence. Leuk Lymphoma. 2009;50:1809–1817.
   PubMed Web of Science ®Google Scholar
• Lim ZY, Pearce L, Ho AY, et al. Delayed attainment of full donor chimaerism following alemtuzumab-based reduced-intensity conditioning haematopoeitic stem cell transplantation for acute myeloid leukaemia and myelodysplastic syndromes is associated with improved outcomes. Br J Haematol. 2007;138:517–526.
   PubMed Web of Science ®Google Scholar
• Altman DG, Lausen B, Sauerbrei W, et al. Dangers of using “optimal” cutpoints in the evaluation of prognostic factors.. J Natl Cancer Inst. 1994;86:829–835.
   PubMed Web of Science ®Google Scholar
• Pascal L, Tucunduva L, Ruggeri A, et al. Impact of ATG-containing reduced-intensity conditioning after single- or double-unit allogeneic cord blood transplantation. Blood. 2015;126:1027–1032.
   PubMed Web of Science ®Google Scholar
• Lindemans CA, Chiesa R, Amrolia PJ, et al. Impact of thymoglobulin prior to pediatric unrelated umbilical cord blood transplantation on immune reconstitution and clinical outcome. Blood. 2014;123:126–132.
   PubMed Web of Science ®Google Scholar
• Lindemans CA, Te Boome LC, Admiraal R, et al. Sufficient Immunosuppression with Thymoglobulin Is Essential for a Successful Haplo-Myeloid Bridge in Haploidentical-Cord Blood Transplantation. Biol Blood Marrow Transplant. 2015;21:1839–1845.
   PubMed Web of Science ®Google Scholar
• Kurosawa S, Yamaguchi T, Uchida N, et al. Comparison of allogeneic hematopoietic cell transplantation and chemotherapy in elderly patients with non-m3 acute myelogenous leukemia in first complete remission. Biol Blood Marrow Transplant. 2011;17:401–411.
   PubMed Web of Science ®Google Scholar
• Estey E, de LM, Tibes R, et al. Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). Blood. 2007;109:1395–1400.
   PubMed Web of Science ®Google Scholar
• Kurosawa S, Yamaguchi T, Miyawaki S, et al. A markov decision analysis of allogeneic hematopoietic cell transplantation versus chemotherapy in patients with acute myeloid leukemia in first remission. Blood. 2010;117:2113–2120.
   PubMed Web of Science ®Google Scholar
• Boyiadzis M, Arora M, Klein JP, et al. Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia. Clin Cancer Res. 2015;21:2020–2028.
   PubMed Web of Science ®Google Scholar
• van Besien K. Allogeneic transplantation for AML and MDS: GVL versus GVHD and disease recurrence. Hematology Am Soc Hematol Educ Program. 2013;2013:56–62.
   PubMedGoogle Scholar
• Bhatia S, Francisco L, Carter A, et al. Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor Study. Blood. 2007;110:3784–3792.
   PubMed Web of Science ®Google Scholar
• Koshy N, Mayer S, Phillips A, et al. Predictors and gvl effects of ucb chimerism after haplo-cord transplant. Blood (Suppl). 2015;126:Abstract 4385.
   Web of Science ®Google Scholar